Kalaris Therapeutics, Inc. (KLRS) › Operating IncomeKalaris Therapeutics, Inc. (KLRS) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2019: -$26.70M2020: -$71.31M2021: -$169.82M2022: -$171.20M2023: -$199.90M2024: -$51.73M2025: -$46.15M-$46.15M2019Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$46.15M+10.8%2024-$51.73M+74.1%2023-$199.90M-16.8%2022-$171.20M-0.8%2021-$169.82M-138.1%2020-$71.31M-167.1%2019-$26.70M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share